ADVFN Logo ADVFN

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Metacrine Inc

Metacrine Inc (MTCR)

0.4949
0.00
( 0.00% )
Updated: 19:00:00
Advanced chart

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
0.4949
Bid
0.4601
Ask
0.475
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Previous Close
0.4949
Open
-
Last Trade
Last Trade Time
-
Average Volume (3m)
-
Financial Volume
-
VWAP
-

MTCR Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

MTCR - Frequently Asked Questions (FAQ)

What is the current Metacrine share price?
The current share price of Metacrine is $ 0.4949
What is the 1 year trading range for Metacrine share price?
Metacrine has traded in the range of $ 0.00 to $ 0.00 during the past year

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ONVOOrganovo Holdings Inc
$ 1.245
(237.40%)
357.5M
WAFUWah Fu Education Group Ltd
$ 3.23
(80.45%)
122.51M
RETOReTo Eco Solutions Inc
$ 0.998
(69.15%)
70.33M
SLXNSilexion Therapeutics Corporation
$ 1.1788
(57.17%)
85.72M
MFImF International Ltd
$ 0.883
(47.24%)
71.84M
YYAIConnexa Sports Technologies Inc
$ 0.754
(-40.63%)
5.55M
RNAZTransCode Therapeutics Inc
$ 4.18
(-38.35%)
541.55k
SXTCChina SXT Pharmaceuticals Inc
$ 4.2175
(-37.24%)
1.12M
ACONAclarion Inc
$ 3.185
(-31.65%)
343.17k
NKLANikola Corporation
$ 0.1795
(-30.10%)
29.73M
ONVOOrganovo Holdings Inc
$ 1.2499
(238.73%)
357.53M
NVDANVIDIA Corporation
$ 129.21
(-0.82%)
220.35M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 14.52
(-16.21%)
150.4M
WAFUWah Fu Education Group Ltd
$ 3.22
(79.89%)
122.51M
PLTRPalantir Technologies Inc
$ 88.06
(-2.89%)
119.41M

MTCR Discussion

View Posts
Renee Renee 2 years ago
MTCR: Liquidation/Final Distribution (no distribution notes by FINRA)

FINRA deleted symbol:

https://otce.finra.org/otce/dailyList?viewType=Deletions
👍️0
Renee Renee 2 years ago
MTCR delisted from the Nasdaq to the OTC:

https://otce.finra.org/otce/dailyList?viewType=Additions
👍️0
HoldEm777 HoldEm777 2 years ago
Insider buying and a buyout… may be already baked in but probably not.
👍️0
CrispCris CrispCris 3 years ago
Double down
👍️0
DewDiligence DewDiligence 3 years ago
50% workforce reduction in R&D:

https://www.globenewswire.com/news-release/2022/02/11/2383703/0/en/Metacrine-Updates-IBD-Clinical-Development-Strategy-and-Implements-Restructuring-Plan.html

What took so long?
👍️0
pitacorp pitacorp 3 years ago
you sure hit the nail on the head with that brilliant conclusion... 4 month old news is going to make this dive now???
👍️0
KeepOn KeepOn 3 years ago
Something happening here?
👍️0
mining101 mining101 3 years ago
Who is following that move??
👍️0
mining101 mining101 3 years ago
Super bullish close
👍️0
JMoneyHoops JMoneyHoops 3 years ago
Yes lost big unfortunately hopefully a bounce PM the love/hate of biotech plays
👍️0
DewDiligence DewDiligence 3 years ago
MTCR addendum: #msg-166460862.
👍️0
DewDiligence DewDiligence 3 years ago
MTCR -50%/AH on discontinuation of FXR/NASH program:

https://www.globenewswire.com/news-release/2021/10/21/2318743/0/en/Metacrine-Reports-Interim-Results-for-MET642-Phase-2a-Trial-in-Patients-with-NASH-and-Announces-a-Strategic-Re-Prioritization-of-Its-Clinical-Development-Programs.html “After a rigorous assessment of our NASH and IBD programs, including the significant capital and resources required to progress these large clinical development programs, we have made the decision to focus Metacrine’s clinical development effort and financial resources on moving MET642 into a Phase 2 trial in IBD in the first half of 2022 and to halt future development of the FXR program in NASH. This decision was influenced in part by a potential delay in confirming appropriate safety margins in our long-term toxicology work that would impact the timing of future NASH studies, but is unlikely to impact timelines for the IBD clinical program.” That was in the seventh paragraph of the PR, LOL.
👍️0
JMoneyHoops JMoneyHoops 3 years ago
Data soon
👍️0
DewDiligence DewDiligence 4 years ago
MTCR 1Q21 results—3/31/21_cash=$84.5M:

https://finance.yahoo.com/news/metacrine-accelerates-met409-clinical-development-200500397.html
👍️0
DewDiligence DewDiligence 4 years ago
MTCR 4Q20 results—12/31/20 cash=$96.2M:

https://www.globenewswire.com/news-release/2021/03/18/2195229/0/en/Metacrine-Provides-Business-Update-and-Reports-Fourth-Quarter-and-Full-Year-2020-Financial-Results.html
👍️0
DewDiligence DewDiligence 4 years ago
MTCR starts phase-2a for MET642—the follow-on FXR agonist to MET409:

https://finance.yahoo.com/news/metacrine-initiates-phase-2a-trial-113000073.html The Phase 2a clinical trial is a 16-week, randomized, placebo-controlled, multi-center trial evaluating the safety, tolerability and pharmacological activity (as measured by liver fat reduction) of MET642 (3 mg and 6 mg) vs placebo. An interim analysis is planned in the fourth quarter of 2021, after approximately 60 patients have completed 16 weeks of treatment. Topline trial results of up to 180 patients are expected to be reported in the first half of 2022. See #msg-162210410 for related info.
👍️0
DewDiligence DewDiligence 4 years ago
MET-409 phase-1b data in NASH don’t look so good:

#msg-162210410
👍️0
doogdilinger doogdilinger 4 years ago
Up +7% pm
👍️0
doogdilinger doogdilinger 4 years ago
Awesome sauce crude buddy, catchin' up on the DD with ya ty
👍️0
doogdilinger doogdilinger 4 years ago
Perfect! I'm playing way more big board this month than pennies! The money flow on big board runners has been utter insanity so far this month!
👍️0
doogdilinger doogdilinger 4 years ago
Nice crude buddy;)
👍️0
crudeoil24 crudeoil24 4 years ago
IPO was last month > 9/16/2020.
👍️0
crudeoil24 crudeoil24 4 years ago
Metacrine shares are trading higher after the company announced it is presenting new data from its MET409 program in NASH at AASLD's The Liver Meeting Digital Experience.
👍️0
crudeoil24 crudeoil24 4 years ago
Metacrine, Inc. is a United States-based biotechnology company. The Company is engaged in developing therapeutics for metabolic diseases. The Company leverages approximately two mechanistically distinct programs to target type 2 diabetes, NASH and other metabolic diseases and liver disorders. The Company focuses on advancing research in nuclear hormone receptors for treatment of metabolic diseases.
👍️0